SA
VNRX logo
VolitionRX Ltd(VNRX)
Closing price · checked 9:50 PM ETAbout this dataData status
$0.16▼-0.00 (-1.58%)
Extended:$0.16-0.00 (-1.23%)· 9:50 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

VolitionRx Limited focuses on developing blood-based diagnostic tests for cancer, leveraging its proprietary Nu.Q technology platform. The company aims to provide non-invasive, cost-effective solutions for early cancer detection, primarily targeting markets in the United States and Europe.

HealthcareMedical - Diagnostics & Researchhigh - The company has high fixed costs associated with R&D and regulatory compliance, which means that as revenue grows, the operating leverage can significantly enhance profitability.

Business Overview

01Diagnostic tests - 100%

VolitionRx generates revenue through the sale of its diagnostic tests, which are designed to detect various types of cancer through blood samples. The company benefits from a high gross margin due to the low cost of goods sold associated with its tests. Its competitive advantage lies in its proprietary technology, which allows for early detection and monitoring of cancer at a fraction of the cost of traditional methods.

What Moves the Stock

Regulatory approvals for new diagnostic tests

Partnerships with healthcare providers or pharmaceutical companies

Clinical trial results demonstrating the efficacy of its tests

Market adoption rates in the U.S. and Europe

Watch on Earnings
Number of tests soldRevenue growth rateGross margin percentage

Risk Factors

Regulatory changes that could impact the approval process for diagnostic tests

Technological disruption from competitors developing superior testing methods

Emerging competitors with advanced diagnostic technologies

Potential for established players to enter the blood-based diagnostic market

High operating losses leading to potential liquidity issues

Dependence on external funding to sustain operations

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - The demand for diagnostic tests can be influenced by healthcare spending, which is correlated with GDP growth and consumer spending.

Interest Rates

Low - As a biotech firm, VolitionRx is less sensitive to interest rates; however, higher rates could impact its ability to raise capital for R&D.

Credit

minimal - The company has a negative debt/equity ratio, indicating it is not reliant on debt financing.

Live Conditions
S&P 500 FuturesRussell 2000 FuturesDow Jones Futures

Profile

growth - Investors looking for high-growth potential in the biotech sector may be attracted to VolitionRx due to its innovative technology.

high - The stock has exhibited significant volatility, as evidenced by its recent performance declines.

Key Metrics to Watch
Regulatory approval timelines for new tests
Market penetration rates in targeted regions
Clinical trial outcomes
Partnership agreements with healthcare institutions
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.